Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 14, 2005 - Issue 7
Submit an article Journal homepage
421
Views
89
CrossRef citations to date
0
Altmetric
Review

Ultra long-acting β2-agonists in development for asthma and chronic obstructive pulmonary disease

Mario Cazzola Department of Respiratory Medicine, A. Cardarelli Hospital, Via del Parco Margherita 24, 80121 Napoli, Italy. [email protected]
,
Maria Gabriella Matera Department of Experimental Medicine, Unit of Pharmacology, 2nd University of Napoli, Napoli, Italy
&
Jan Lötvall Department of Respiratory Medicine and Allergology, Göteborg University, Göteborg, Sweden
Pages 775-783 | Published online: 15 Jul 2005

Bibliography

  • GLOBAL INITIATIVE FOR ASTHMA: Global strategy for asthma management and prevention. NHLBI/WHO Workshop Report (2002):02–3659.
  • CELLI BR, MacNEE W: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir 1 (2004) 23:932–946.
  • LIP WORTH BJ: Airway subsensitivity with long-acting 02-agonists. Is there cause for concern? Drug Sal (1997) 16:295–308.
  • WALDECK B: Some pharmacodynamic aspects on long-acting 0-adrenoceptor agonists. an. Pharmacol (1996) 27:575–580.
  • MOLFINO NA: Drugs in clinical development for chronic obstructive pulmonary disease. Respiration (2005) 72:105–112.
  • GUMBHIR-SHAH K, KELLERMAN DJ, DEGRAW S, KOCH P, JUSKO WJ: Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers. Clin. Pharmacol (1998) 38:1096–1011.
  • HANDLEY D: The asthma-like pharmacology and toxicology of the (5)-isomers of 0-agonists. J. Allergy Clin. Immunol (1999) 104:S69–S76.
  • WALDECK B: 0-Adrenoceptor agonists and asthma-100 years of development. Eur. Pharmacol (2002) 445:1–12.
  • HANDLEY DA, MORLEY J: The pursuit of precision pharmaceuticals: divergent effects of 13-2 agonist isomers. Expert Opin. Investig. Drugs (1998) 7:1601–1616.
  • RAMSAY CM, COWAN J, FLANNERY E, McLACHLAN C, TAYLOR DR: Bronchoprotective and bronchodilator effects of single doses of (5)-salbutamol, (R)-salbutamol and racemic salbutamol in patients with bronchial asthma. Eur. I Clin. Pharmacol (1999) 55:353–359.
  • COCKROFT DW, SWYSTUN VA: Functional antagonism: tolerance produced by inhaled 132 agonists. Thorax (1996) 51:1051–1056.
  • LOT VALL J, PALMQVIST M, ANKERST J et al.: The effect of formoterol over 24 h in patients with asthma: the role of enantiomers. Pulm. Pharmacol Ther. (2005) 18:109–113.
  • ZHANG M, FAWCETT JP, KENNEDY JM, SHAW JP: Stereoselective glucuronidation of rac-FMT by human liver microsomes. Br.Pharmacol (2000)49:152–157.
  • ANON: Novel long-acting 02 agonists: Glaxo Wellcome plc: W002070490 & W002076933. Current Opin. Ther. Patents (2003) 13:273–277.
  • ANON: Arformoterol: (R,"eformoterol, (R,R)-formoterol, arformoterol tartrate, eformoterol-sepracor, formoterol-sepracor, (R,R)-eformoterol, (',R)-formoterol. Drugs R D (2004) 5:25–27.
  • KIKKAWA H, NAITO K, IKEZAWA K: Tracheal relaxing effects and 02-selectivity of TA-2005, a newly developed bronchodilating agent, in isolated guinea-pig tissues. Jpn.j Pharmacol (1991) 57:175–185.
  • VOSS H-P, DONNELL D, BAST A: Atypical molecular pharmacology of a new long-acting 02-adrenoceptor agonist, TA-2005. Eur. Pharmacol (1992) 227:403–409.
  • STANDIFER KM, PITHA J, BAKER SP:Carbostyril-based 0-adrenergic agonists: evidence for long lasting or apparent irreversible receptor binding and activation of adenylate cyclase activity in vitro. Naunyn-Schmiedeberg's Arch. Pharmacol (1989) 339:129–137.
  • KIKKAWA H, ISOGAYA M, NAGAO T, KUROSE H: The role of the seventh transmembrane region in high affinity binding of a 02-selective agonist TA-2005. Mol Pharmacol (1998) 53:128–134.
  • VOSS HP, SHUKRULA S, WU TS, DONNELL D, BAST A: A functional 132 adrenoceptor-mediated chronotropic response in isolated guinea pig heart tissue: selectivity of the potent 32 adrenoceptor agonist TA 2005. J. Pharmacol Exp. Ther. (1994) 271:386–389.
  • KIKKAWA H, KANNO K, IKEZAWA K: TA-2005, a novel, long-acting, and selective 02-adrenocepter agonist: characterization of its in vivo bronchodilating action in guinea pigs and cats in comparison with other 02-agonists. Biol. Pharm. Bull. (1994) 17:1047–1052.
  • VOSS H-P: Long-acting 02-adrenoceptor agonists in asthma: molecular pharmacological aspects. Thesis, VrijeUniversiteit, Amsterdam (1994).
  • CHIESI FARMACEUTICI STA. INVESTIGATOR'S BROCHURE: CHF 4226. Data on file. (2004).
  • INVESTIGATIONAL DRUGS DATABASE: 251789.
  • INVESTIGATIONAL DRUGS DATABASE: 257188.
  • ROSSONI G, MANFREDI B, RAZZETTI R, CIVELLI M, BONGRANI S, BERTI F: Positive interaction of the 02-agonist CHF 4226.01 with budesonide in the control of bronchoconstriction induced by acetaldehyde in the guinea-pigs. Br. Pharmacol (2005) 144:422–429.
  • LEWIS CA, JORDAN L, WYSS D, BAYLEY D, MAAS J, BATTRAM C: QAB-149, a novel 24-hour 02-agonist, demonstrates a long duration of action and fast onset in vitro and in vivo in the guinea pig. Proc. Am. Thome Soc. (2005) 2:A355.
  • NALINE E, MOLIMARD M, FAIRHURST R, TRIFILIEFF A, ADVENIER C: Duration and onset of action of QAB-149, a novel 24-hour 132-agonist, on the isolated human bronchus. Proc. Am. Thome Soc. (2005) 2:A356.
  • NALINE E, MOLIMARD M, FAIRHURST R, TRIFILIEFF A, ADVENIER C: Pharmacological characterization of QAB-149, a novel 24-hour 02-agonist, on the isolated human bronchus. Proc. Am. Thome Soc. (2005) 2:A356.
  • BATTRAM CH, MOK J, LEWIS CA: Once-daily administration of QAB-149 does not induce tachyphylaxis in vivo. Proc. Am. Thome Soc. (2005) 2:A356.
  • BEEH K-M, SCHELFOUT V, GRONKE L, KANNIESS F, CAMERON R, VAN AS A: QAB149: the first once-daily 02-agonist with 24-hour bronchodilation. Proc. Am. Thome Soc. (2005) 2:A356.
  • INVESTIGATIONAL DRUGS DATABASE: 467458.
  • ANON: New long-acting 02-agonists. Theravance, Inc: W02004011416. Current Opin. Ther. Patents (2004) 14:1385–1388.
  • INVESTIGATIONAL DRUGS DATABASE: 515950.
  • INVESTIGATIONAL DRUGS DATABASE: 516398.
  • INVESTIGATIONAL DRUGS DATABASE: 572384.
  • INVESTIGATIONAL DRUGS DATABASE: 518158.
  • INVESTIGATIONAL DRUGS DATABASE: 478510.
  • INVESTIGATIONAL DRUGS DATABASE: 515950.
  • INVESTIGATIONAL DRUGS DATABASE: 572384.
  • ALIKHANI V, BEER D, BENTLEY D et al.: Long-chain formoterol analogues: an investigation into the effect of increasing amino-substituent chain length on the 02-adrenoceptor activity. Bioorg. Med. Chem. Lett. (2004) 14:4705–4710.
  • GAN LL, WANG MW CHENG MS, PAN L: Trachea relaxing effects and 02-selectivity of SPFF, a newly developed bronchodilating agent, in guinea pigs and rabbits. Biol. Pharm. Bull. (2003) 26:323–328.
  • BERGENDAL A, JOHANSSON A, BAKE B, LOTVALL J, SKOOGH BE, LOFDHAL CG: Airway effects of salmeterol in healthy individuals. Pulm. Pharmacol. (1995) 8:283–288.
  • PALMQVIST M, IBSEN T, MELLEN A, LOT VALL J: Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am. I Respir. Crit. Care Med. (1999) 160:244–249.
  • BATEMAN ED, BOUSHEY HA, BOUSQUET J et al.: Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am. J. Respir Crit. Care Med. (2004) 170:836–844.
  • ZETTERSTROM 0, BUHL R, MELLEM H et al: Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur. Respir J. (2001) 18:262–268.
  • AALBERS R, BACKER V, KAVA TT et al: Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curl: Med. Res. Opin. (2004) 20:225–240.
  • BALANAG VM, YUNUS F, YANG P-C, JORUP C: Budesonide/formoterol in a single inhaler is as effective and well tolerated as salbutamol in relieving acute asthma in adults and adolescents. Eur. Respir J. (2003) 22:445s.
  • O'BYRNE PM, BISGAARD H, GODARD PP et al: Budesonide/ formoterol combination therapy as both maintenance and reliever medication in asthma. Am. J. Respir. Crit. Care Med. (2005) 171:129–136.
  • CAZZOLA M, SANTUS P, DI MARCO F et al: Onset of action of formoterol/ budesonide in single inhaler vs. formoterol in patients with COPD. Pulm. Pharmacol. Ther. (2004) 17:121–125.
  • CAZZOLA M: Single inhalor budesonide/ formoterol in exacerbations of chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. (2005) (In Press).
  • INVESTIGATIONAL DRUGS DATABASE: 515870.
  • INVESTIGATIONAL DRUGS DATABASE: 515899.
  • TENNANT RC, ERIN EM, BARNES PJ, HANSEL TT: Long-acting 02-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified? Curl: Opin. Pharmacol. (2003) 3:270–276
  • TASHKIN DP, COOPER CB: The role of long-acting bronchodilators in the management of stable COPD. Chest (2004) 125:249–259.
  • CAZZOLA M, DI MARCO F, SANTUS P et al: The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm. Pharmacol. Ther. (2004) 17:35–39.
  • CAZZOLA M, CENTANNI S, SANTUS P et al: The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir. Med. (2004) 98:1214–1221.
  • PALMQVIST M, PERSSON G, LAZER L,ROSENBORG J, LARSSON P, LOT VALL J: Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur. Respir J. (1997) 10:2484–2489.

Websites

  • http://www.sepracor.com/therap/ arformoterol.html Sepracor website on arfomoterol
  • http://www.thisisms.com/ modules.php?name=News&file=article&sid =182 Information on multiple sclerosis.
  • http://www.bioworld.com/servlet/ com.accumedia.web.Dispatcher?next=bioW orldHeadlines_article&forceid=31561 BioWorld Online website.
  • http://www.gsk.com/financial/ product_pipeline.htm GSK product development pipeline.
  • http://www.3m.com/us/healthcare/pharma/ pharma_clinicaljhtml 3M website.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.